Ann: Results from Data Confirmation Study, page-274

Funny outcome from the failure of the Covid screening tool in this repeat study. The board recommended/justified the takeover based on the need for capital in the future. A large part of that need for capital was for the further study/testing/approval then commercialisation of this Covid screening tool. As this repeat testing has failed and unless they can find out why, there should be no further development of this tool and no further need for capital.

As a result RAP needs less capital going forward. SleepCheck seems unlikely to make any significant revenue even with FDA approval. The main game is ResAppDX and capital is needed to get it to FDA approval and further commercialisation. All other product development should be put on hold unless they can find a partner to invest in it.